Portage Biotech Inc., a clinical-stage immuno-oncology company focused on overcoming cancer treatment resistance, entered into an agreement with Merck.
Researchers at Moffitt Cancer Center have been awarded a $22.4 million grant from the U.S. Department of War to lead studies and clinical trials for leptomeningeal disease, a devastating complication of breast and other cancers that spreads to the coverings of the brain and spinal cord.
